<DOC>
	<DOCNO>NCT02269267</DOCNO>
	<brief_summary>This non-randomized , prospective , single-group longitudinal study . The purpose study improve decision make process use physician patient consider stop Tyrosine Kinase Inhibitor ( TKI ) medication .</brief_summary>
	<brief_title>The Life After Stopping Tyrosine Kinase Inhibitors Study ( The LAST Study )</brief_title>
	<detailed_description>This non-randomized , prospective , single-group longitudinal study . The overall objective improve decision make TKI discontinuation eligible CML patient . Patients CML treatment imatinib , dasatinib , nilotinib , bosutinib confirm deep molecular response stop TKI . Confirmed deep molecular response define BCR-ABL &lt; 0.01 % , ( &gt; MR4 i.e . &gt; 4 log reduction ) least 2 year . The study closely monitor patient use standard RQ-PCR test molecular recurrence , test monthly 6 month , every month 24 month , quarterly 36 month . Concurrently , study ass wide range PROs stop TKIs discontinuation conjunction PCR testing , though few time point , utilizing online and/or phone questionnaire . Patients molecular CML recurrence base RQ-PCR restart imatinib , dasatinib , nilotinib , bosutinib continue monitor disease status health status end study .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tin Fluorides</mesh_term>
	<criteria>1 . Age 18 old time study entry 2 . Willing able give inform consent 3 . Diagnosed CML chronic phase either b3a2 ( e14a2 ) b2a2 ( e13a2 ) variant give rise p210 BCRABL protein 4 . Currently take imatinib , dasatinib , nilotinib bosutinib 5 . Patient TKI therapy least 3 year 6 . Documented BCRABL &lt; 0.01 % ( &gt; MR4 i.e . &gt; 4 log reduction ) undetectable BCRABL PCR least 2 year accord patient 's local lab 7 . Documented BCRABL &lt; 0.01 % ( &gt; MR4 i.e . &gt; 4 log reduction ) undetectable BCRABL least 3 time prior screen accord patient 's local lab 8 . Two ( 2 ) Screening PCRs complete result &lt; 0.01 % ( &gt; MR4 i.e &gt; 4 log reduction ) central lab 9 . Has number TKIs , resistant TKI ( change make intolerance allow ) 10 . Patient compliant therapy per treat physician 1 . Prior hematopoietic stem cell transplantation 2 . Poor compliance take TKI 3 . Unable comply lab appointment schedule PRO assessment 4 . Life expectancy le 36 month 5 . Patients resistant previous TKI therapy eligible 6 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>